High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization

Ai,Ning; Liu,Wei; Li,Zhi‑Gang; Ji,Hong; Li,Bo; Yang,Guang

doi:10.3892/ol.2017.6697

High expression of GP73 in primary hepatocellular carcinoma and its function in the assessment of transcatheter arterial chemoembolization

Authors:
- Ning Ai
- Wei Liu
- Zhi‑Gang Li
- Hong Ji
- Bo Li
- Guang Yang
View Affiliations

Affiliations: Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Department of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China
Published online on: August 1, 2017 https://doi.org/10.3892/ol.2017.6697
Pages: 3953-3958

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Golgi glycoprotein 73 (GP73) is a type II Golgi transmembrane protein and a potential novel marker for the diagnosis of primary hepatocellular carcinoma (PHC). However, its reliability as a serum marker for the diagnosis of PHC following transcatheter arterial chemoembolization (TACE) remains unknown. The aim of the present study was to evaluate the diagnostic value of serum GP73 levels in patients with PHC, to determine its diagnostic accuracy in patients with PHC following TACE. Reverse transcription‑quantitative polymerase chain reaction analysis was used to measure GP73 expression in PHC and adjacent para‑carcinomatous liver tissue in 40 patients with PHC, and 15 normal liver samples from benign hepatic tumors. The associations between GP73 expression levels with clinicopathological characteristics of the patients were also analyzed. Serum GP73 levels were detected by ELISA in 68 patients with PHC following TACE and 29 healthy individuals. The levels of serum GP73 were tested 2 days prior to intervention, and 7 and 30 days following TACE. GP73 mRNA expression levels in PHC were significantly higher than in the corresponding para‑carcinomatous liver and normal liver samples. High expression levels of GP73 mRNA were associated with tumor size, vascular invasion and tumor differentiation, suggesting augmented tumor invasion and metastasis. The expression levels of serum GP73 were markedly higher in the patients with PHC compared with healthy individuals. Serum GP73 levels in the 68 patients with PHC were higher compared with the 29 normal controls [152.5 (76.4‑284.5) compared with 49.3 (12.6‑26.7) µg/l], and the difference was statistically significant (P<0.01). High levels of serum GP73 were associated with tumor differentiation. The levels of Barcelona clinic liver cancer stage A, B and C were 92.12 (38.9‑135.2), 122.9 (55.2-178.5), and 162.55 (110.8‑232.9) µg/l, respectively (P<0.05). The serum GP73 levels 7 days following TACE [99.2 (66.7‑150.8)] were significantly lower than prior to TACE, and the difference was statistically significant (P<0.05). In the group of 49 patients with serum α‑fetoprotein (AFP) levels <400 µg/l, the serum GP73 levels were >132 µg/l. Serum GP73 levels may serve as a potential independent diagnostic marker for PHC, and the combined evaluation of serum GP73 and AFP may increase the diagnostic efficiency of PHC. Significant overexpression of GP73 mRNA was associated with aggressive PHC. However, further research is required to confirm the potential of GP73 as a diagnostic marker.

View Figures

View References

1	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
2	Mao Y, Yang H, Xu H, Lu X, Sang X, Du S, Zhao H, Chen W, Xu Y, Chi T, et al: Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 59:1687–1693. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z and Fimmel CJ: GP73, a novel Golgi-localized protein uprcgulated by viral infection. Gene. 249:53–65. 2000. View Article : Google Scholar : PubMed/NCBI
4	Zhang F, Gu Y, Li X, Wang W, He J and Peng T: Upregulated Golgi phosphoprotein 2 (GOLPH2) expression in lung adenocarcinoma tissue. Clin Biochem. 43:983–991. 2010. View Article : Google Scholar : PubMed/NCBI
5	Nagasue N, Galizia G, Kohno H, Chang YC, Hayashi T, Yamanoi A, Nakamura T and Yukaya H: Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: A retrospective comparision of 138 liver resection. Surgery. 106:81–86. 1989.PubMed/NCBI
6	Benowitz S: Liver cancer biomarkers struggling to succeed. J Natl Cancer Inst. 99:590–591. 2007. View Article : Google Scholar : PubMed/NCBI
7	Edmondson HA and Steiner PE: Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
8	Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M and Rodés J: EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol. 35:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
9	Triantos C, Zisimopoulos K, Tsochatzis E, Vlachogiannakos J, Manolakopoulos S, Rigamonti C, Goulis J, Manesis E, Anastasiou J, Papalexi F, et al: 207 Meld vs cps for prognosis in cirrhosis. Results from a multicentre study. J Hepatol. 52:(Suppl 1). S892010. View Article : Google Scholar
10	Bai H: Manual of tumor diagnosis and treatment for primary physicians. Peking University Medical Press; Beijing: pp. 3562008
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Seldinger SI: Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta Radiol. 39:368–376. 1953. View Article : Google Scholar : PubMed/NCBI
13	Saffroy R, Pham P, Reffas M, Takka M, Lemoine A and Debuire B: New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 45:1169–1179. 2007. View Article : Google Scholar : PubMed/NCBI
14	Liu X, Wan X, Li Z, Lin C, Zhan Y and Lu X: Golgi protein 73 (GP73), a useful serum marker in liver diseases. Clin Chem Lab Med. 49:1311–1316. 2011. View Article : Google Scholar : PubMed/NCBI
15	Bruix J and Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology. 42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
16	Oka H, Tamori A, Kuroki T, Kobayashi K and Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatol. 19:61–66. 1994. View Article : Google Scholar
17	Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, Coderc E, Reboullet P and Beaugrand M: Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol. 20:65–71. 1994. View Article : Google Scholar : PubMed/NCBI
18	Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G and Pisi E: Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer. 78:977–985. 1996. View Article : Google Scholar : PubMed/NCBI
19	Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale MA, D'Amelio A, Lok AS and Block TM: GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 43:1007–1012. 2005. View Article : Google Scholar : PubMed/NCBI
20	Norton PA, Comunale MA, Krakover J, Rodemich L, Pirog N, D'Amelio A, Philip R, Mehta AS and Block TM: N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem. 104:136–149. 2008. View Article : Google Scholar : PubMed/NCBI
21	Riener MO, Stenner F, Liewen H, Soll C, Breitenstein S, Pestalozzi BC, Samaras P, Probst-Hensch N, Hellerbrand C, Müllhaupt B, et al: Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serummarker in hepatocellular carcinomas. Hepatology. 49:1602–1609. 2009. View Article : Google Scholar : PubMed/NCBI
22	Poon Tung-Ping R, Fan ST and Wong J: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 232:10–24. 2000. View Article : Google Scholar : PubMed/NCBI
23	Shimada K, Sano T, Sakamoto Y and Kosuge T: A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy. Cancer. 104:1939–1947. 2005. View Article : Google Scholar : PubMed/NCBI
24	Hu JS, Wu DW, Liang S and Miao XY: GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol. 27:339–345. 2010. View Article : Google Scholar : PubMed/NCBI
25	Zhou Y, Yin X, Ying J and Zhang B: Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: A diagnostic meta-analysis. BMC Cancer. 12:172012. View Article : Google Scholar : PubMed/NCBI
26	Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Gräff A, Gusmirovic I, Solomon H, Luxon BA, Bacon BR and Fimmel CJ: Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 99:1087–1095. 2004. View Article : Google Scholar : PubMed/NCBI